Having trouble accessing articles? Reset your cache.

Plucked from the discard pile

Bristol-Myers Squibb Co. may have jumped the gun when it dropped development of tesmilifene after the compound failed to improve response rates and progression-free survival in a Phase III breast cancer trial. As it turns out, tesmilifene actually increased overall survival.

Now YM Biosciences Inc. is preparing another go with tesmilifene in breast cancer, after initially picking up the discarded compound based on its promising activity in prostate cancer.

In 2000, YM

Read the full 714 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers